Natera
🇺🇸 NASDAQ:NTRA
•
Dec 31, 2024
Natera Q4 2024 Earnings Report
Natera reported strong revenue growth in Q4 2024, driven by increased test volume and higher average selling prices.
Key Takeaways
Natera's Q4 2024 revenue increased by 53% year-over-year to $476.1 million, primarily due to higher product revenue. The company processed 792,800 tests in the quarter, up 26.5% from Q4 2023. Gross margin improved to 62.9%, reflecting cost efficiencies. Net loss narrowed to $53.8 million from $78.0 million in the previous year.
Q4 2024 revenue grew 53% to $476.1 million, driven by strong product sales.
Gross margin improved to 62.9% from 51.4% in Q4 2023.
Processed 792,800 tests, up 26.5% year-over-year.
Net loss reduced to $53.8 million from $78.0 million in Q4 2023.
Natera Revenue
Natera EPS
Natera Revenue by Segment
Forward Guidance
Natera anticipates strong revenue growth in 2025, with revenue expected to reach between $1.87 billion and $1.95 billion, while maintaining a gross margin of 60% to 64%.
Positive Outlook
- Expected revenue growth to $1.87 billion - $1.95 billion in 2025.
- Gross margin projected to be in the range of 60% to 64%.
- Continued test volume expansion expected to drive revenue growth.
- Ongoing operational efficiencies expected to improve profitability.
- Strong cash position to support future growth and innovation.
Challenges Ahead
- Potential challenges in reimbursement policies could impact revenue.
- Higher R&D expenses expected due to new product investments.
- Competitive pressures in the genetic testing market remain high.
- Regulatory uncertainties could impact future test offerings.
- Macroeconomic conditions may affect healthcare spending and adoption rates.